These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38843737)

  • 1. 'Matters-of-concern' associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study.
    Parkin S; Neale J; Strang J
    Int J Drug Policy; 2024 Jul; 129():104470. PubMed ID: 38843737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study.
    Parkin S; Neale J; Strang J
    Int J Drug Policy; 2023 Dec; 122():104221. PubMed ID: 37865052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study.
    Neale J; Parkin S; Strang J
    Subst Abuse Treat Prev Policy; 2023 Jun; 18(1):37. PubMed ID: 37349776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study.
    Nordgren J; Monwell B; Johnson B; Gunnarsson NV; Capusan AJ
    Addict Sci Clin Pract; 2024 Apr; 19(1):25. PubMed ID: 38581022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
    Tompkins CNE; Neale J; Strang J
    J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do patients feel during the first 72 h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis.
    Neale J; Parkin S; Strang J
    Addiction; 2023 Jul; 118(7):1329-1339. PubMed ID: 36808168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
    Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
    Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Prescribed Substance Use during the First Month of Treatment by People Receiving Depot Buprenorphine for Opioid Use Disorder.
    Parkin S; Neale J; Strang J
    Subst Use Misuse; 2023; 58(13):1696-1706. PubMed ID: 37571999
    [No Abstract]   [Full Text] [Related]  

  • 11. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct induction onto high-dose long-acting injectable buprenorphine: A case series.
    Naren T; Cook J; MacCartney P
    Australas Psychiatry; 2024 Jun; 32(3):238-241. PubMed ID: 38444394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
    Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.
    Barnett A; Pienaar K; Lubman DI; Arunogiri S; Phan V; Hayes V; Lintzeris N; Savic M
    Int J Drug Policy; 2024 May; 127():104399. PubMed ID: 38636315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
    Soyka M; Groß G
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
    Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
    J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
    Neale J; Tompkins CNE; Strang J
    Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Acting Injectable Buprenorphine for Opioid Use Disorder: A Qualitative Analysis of Patients' Interpersonal Relationships during the First Year of Treatment.
    Neale J; Strang J
    Subst Use Misuse; 2024; 59(14):2064-2072. PubMed ID: 39165015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.